{"id":"ars-1","safety":{"commonSideEffects":[]},"_chembl":{"chemblId":"CHEMBL1206015","moleculeType":"Small molecule","molecularWeight":"320.28"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"ARS-1 works by [insert explanation here, if known].","oneSentence":"ARS-1 is a small molecule that targets the [insert target here, if known].","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T02:29:14.331Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Phase 2 for [insert indication here, if known]"}]},"trialDetails":[{"nctId":"NCT05496465","phase":"PHASE2","title":"Safety and Efficacy of Intranasal Epinephrine After Administration of ARS -1 in Subjects With Frequent Urticaria Flares","status":"COMPLETED","sponsor":"ARS Pharmaceuticals, Inc.","startDate":"2022-07-28","conditions":"Urticaria","enrollment":24},{"nctId":"NCT05540288","phase":"PHASE3","title":"NAlmefene Versus Placebo in Addition to Treatment as Usual on Craving in Behavioural Addictions","status":"RECRUITING","sponsor":"Nantes University Hospital","startDate":"2023-03-31","conditions":"Behavioural Addiction","enrollment":266},{"nctId":"NCT05363670","phase":"PHASE2","title":"Administration of ARS-1 or Albuterol in Subjects With Persistent Asthma","status":"COMPLETED","sponsor":"ARS Pharmaceuticals, Inc.","startDate":"2022-07-28","conditions":"Asthma","enrollment":18},{"nctId":"NCT04930900","phase":"PHASE1","title":"Pharmacokinetics of Adrenaline After Administration of ARS -1 in Subjects With Upper Respiratory Tract Infection","status":"COMPLETED","sponsor":"ARS Pharmaceuticals, Inc.","startDate":"2021-08-09","conditions":"Upper Respiratory Tract Infection","enrollment":15}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":67,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"ARS-1","genericName":"ARS-1","companyName":"ARS Pharmaceuticals, Inc.","companyId":"ars-pharmaceuticals-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"ARS-1 is a small molecule that targets the [insert target here, if known]. Used for Phase 2 for [insert indication here, if known].","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}